5 of Last Week's Biggest Losers

There's never a shortage of losers in the stock market.

Let's take a closer look at five of this past week's biggest sinkers.

Company

Oct. 19

Weekly Loss

My Watchlist

Apollo Group (Nasdaq: APOL  )

$20.39

(29%)

Add

Isis Pharmaceuticals (Nasdaq: ISIS  )

$9.35

(26%)

Add

Advanced Micro Devices (NYSE: AMD  )

$2.18

(20%)

Add

Clearwire (Nasdaq: CLWR  )

$1.85

(20%)

Add

MannKind (Nasdaq: MNKD  )

$1.98

(16%)

Add

Source: Barron's.

Apollo Group flunked out after continuing softness for the for-profit post-secondary educator. The parent company of the University of Phoenix announced that it would close some of its smaller campuses and trim its payroll.

Isis may have received a nod of approval from an FDA advisory committee for its cholesterol-tackling drug, but the concern here is that a nasty potential side effect -- 3% of the patients taking Kynamro during the clinical study developed tumors -- will restrict the drug's recommended usage.

Advanced Micro Devices took a hit after the PC chip maker posted disastrous quarterly results. If the 25% plunge in revenue or the larger-than-expected deficit doesn't scare you, the desperate move to dismiss 15% of its workforce in a cost-shaving move should do the trick.

Clearwire has been volatile since Softbank announced that it would be taking a 70% stake in its ally Sprint Nextel (NYSE: S  ) . Many speculated that Sprint would seek to acquire Clearwire outright, but now it seems as if the country's third-largest wireless carrier may be content with merely a majority stake in Clearwire.

MannKind took one giant leap down after announcing plans to sell as many as 140 million shares of stock. Investors seemed to disregard the fact that MannKind needs the money for new trials to try to get its inhaled insulin treatment moving again. The transaction will ease the company's leveraged burden by swapping debt for equity. All that investors saw last week was dilution, so down went MannKind.

Ready for a bounce
It was a rough week for these five stocks. If you want to shake yesterday's losers and ride tomorrow's winners, check out our special 
 free report: "3 Stocks That Will Help You Retire Rich." In it, our analysts name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to get your free copy.

Longtime Fool contributor Rick Aristotle Munarriz has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend MannKind. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 22, 2012, at 5:57 PM, WCoastGuynCA wrote:

    In regards to Mannkind, Al Mann, the company's billionaire C.E.O. did convert over a $100 million in debt at $2.59 share. There is speculation that the intent of all the debt being converted to equity is that the company could be a takeover target by a "big pharma" suitor.

    If Mannkind is granted "priority review" status for Afrezza approval could happen as early as September of next year.

    At under $2.00 a share and with funding secured to operate through approval now might be a good time to buy/add shares for the approval run-up especially since a buyout or partnership could happen at any time.

Add your comment.

DocumentId: 2068357, ~/Articles/ArticleHandler.aspx, 4/21/2014 3:50:09 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement